ArTS Archivio della ricerca di Trieste

FEDERICO, STEPHANIE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.727
EU - Europa 4.184
AS - Asia 2.873
SA - Sud America 441
AF - Africa 135
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 13
AN - Antartide 1
Totale 16.389
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.608
SG - Singapore 976
IT - Italia 952
CN - Cina 837
SE - Svezia 809
PL - Polonia 433
BR - Brasile 371
DE - Germania 366
HK - Hong Kong 324
UA - Ucraina 275
FR - Francia 251
GB - Regno Unito 211
RU - Federazione Russa 190
FI - Finlandia 167
NL - Olanda 146
TR - Turchia 133
KR - Corea 127
VN - Vietnam 112
IN - India 104
IE - Irlanda 102
BG - Bulgaria 76
CA - Canada 64
BE - Belgio 44
BD - Bangladesh 42
JP - Giappone 38
MA - Marocco 36
AT - Austria 33
CZ - Repubblica Ceca 31
CH - Svizzera 27
ES - Italia 27
ID - Indonesia 25
IQ - Iraq 25
CI - Costa d'Avorio 22
AR - Argentina 20
MY - Malesia 18
ZA - Sudafrica 18
MX - Messico 16
SA - Arabia Saudita 16
EC - Ecuador 15
EG - Egitto 14
IL - Israele 14
LT - Lituania 14
PK - Pakistan 13
CO - Colombia 12
UZ - Uzbekistan 12
AU - Australia 11
EU - Europa 11
AZ - Azerbaigian 9
BZ - Belize 9
JM - Giamaica 8
IR - Iran 7
KE - Kenya 7
NG - Nigeria 7
SN - Senegal 7
TG - Togo 7
VE - Venezuela 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
TN - Tunisia 6
TT - Trinidad e Tobago 6
DZ - Algeria 4
JO - Giordania 4
NZ - Nuova Zelanda 4
PE - Perù 4
PR - Porto Rico 4
TW - Taiwan 4
BB - Barbados 3
GR - Grecia 3
HN - Honduras 3
HU - Ungheria 3
KZ - Kazakistan 3
MN - Mongolia 3
PT - Portogallo 3
RS - Serbia 3
AL - Albania 2
BO - Bolivia 2
BY - Bielorussia 2
CR - Costa Rica 2
DK - Danimarca 2
GE - Georgia 2
KG - Kirghizistan 2
KW - Kuwait 2
LV - Lettonia 2
NO - Norvegia 2
OM - Oman 2
PS - Palestinian Territory 2
PY - Paraguay 2
RO - Romania 2
SI - Slovenia 2
TH - Thailandia 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AQ - Antartide 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CG - Congo 1
DO - Repubblica Dominicana 1
EE - Estonia 1
Totale 16.371
Salva come PNG Salva come JPEG
Città #
Dallas 2.465
Woodbridge 595
Houston 593
Fairfield 591
Singapore 576
Ashburn 549
Ann Arbor 447
Warsaw 422
Chandler 351
Hefei 331
Hong Kong 316
Wilmington 300
Trieste 294
Jacksonville 264
Seattle 260
Cambridge 218
Beijing 192
Princeton 133
Munich 131
Boardman 130
Seoul 119
Columbus 111
Izmir 107
The Dalles 90
Dublin 86
London 80
Los Angeles 77
Santa Clara 76
Sofia 76
Buffalo 72
Moscow 67
New York 59
Menlo Park 58
Milan 55
Frankfurt am Main 48
São Paulo 44
North Bergen 42
West Jordan 41
Turku 39
Mestre 37
Düsseldorf 36
Brussels 34
Ho Chi Minh City 33
Rome 33
San Diego 33
Shanghai 32
Helsinki 31
Verona 29
Amsterdam 28
Council Bluffs 27
Guangzhou 27
Sacile 26
Casablanca 25
Vienna 25
Toronto 24
Abidjan 22
Bremen 22
Falls Church 21
Brno 20
Hanoi 20
Phoenix 20
Redwood City 20
Tokyo 19
Bern 18
Brooklyn 18
Chicago 18
Nuremberg 18
Lauterbourg 16
New Delhi 14
Pittsburgh 14
Fremont 13
Camerino 12
Codroipo 12
Philadelphia 12
Torre Del Greco 12
Udine 12
Des Moines 11
Dhaka 11
Norwalk 11
Padova 11
Redondo Beach 11
Rio de Janeiro 11
Tappahannock 11
Tashkent 11
Dearborn 10
Ferrara 10
Kocaeli 10
Montreal 10
San Francisco 10
Scottsdale 10
Baku 9
Cairo 9
Jakarta 9
Nanchang 9
Quito 9
Treviso 9
Tulsa 9
Cividale del Friuli 8
Dong Ket 8
Florence 8
Totale 11.573
Salva come PNG Salva come JPEG
Nome #
1,2,4-Triazolo[1,5-a]-1,3,5-triazine nucleus: a possible template for adenosine receptor subtypes. 776
[1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A3 adenosine receptor subtype 675
[1,2,4]Triazolo[1,5-a][1,3,5]Triazine Derivatives as Antagonists for the Adenosine Receptors: a Preliminary Study on Affinity at the A3 Subtype 598
1,2,4]Triazolo[1,5-c]pyrimidines as New Potent Human A3 Adenosine Receptor Antagonists. 581
[1,2,4]Triazolo[1,5-c]pyrimidine Nucleus as Adenosine Receptor Antagonists: Shift in Selectivity from A2A to A3 Adenosine Receptors. 548
[1,2,4]triazolo[1,5-c]pyrimidines as A(3) adenosine receptor antagonists 548
[1,2,4]Triazolo[1,5-c]pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer Cell Lines 531
Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment 408
The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives 402
A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition 343
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists 305
null 245
Scaffold decoration at positions 5 and 8 of 1,2,4-triazolo[1,5- c ]pyrimidines to explore the antagonist profiling on adenosine receptors: A preliminary structure-activity relationship study 242
A2Aadenosine receptor antagonists as therapeutic candidates: Are they still an interesting challenge? 242
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors 235
Advances in Computational Techniques to Study GPCR-Ligand Recognition 224
Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1 δinhibitors 222
null 217
null 214
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 199
Chemical probes for the adenosine receptors 199
null 197
Mixed-reversible and covalent kinase inhibition as a possible new strategy to treat neuro-inflammatory/degenerative diseases 193
A facile and novel synthesis of N2-, C6-substituted pyrazolo[3,4- d ]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists 186
N8-Isopentyl and N8-Phenylethyl Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine Derivatives as Adenosine Receptor Antagonists 183
Design, synthesis and evaluation of new indolylpyrimidylpiperazines for gastrointestinal cancer therapy 180
Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems 180
Targeting Protein Kinase CK1δ with Riluzole: Could It Be One of the Possible Missing Bricks to Interpret Its Effect in the Treatment of ALS from a Molecular Point of View? 176
Structural investigations on a novel class of 1,2,4-triazolo[1,5-c]pyrimidines as adenosine receptor antagonists. 170
A novel conjugated agent between dopamine and an A2A adenosine receptor antagonists as a potential anti-Parkinson multitarget approach. 164
null 161
Chapter 1: A3 adenosine receptor ligands in the treatment of inflammation and cancer 161
Glycogen Synthase Kinase 3β Involvement in Neuroinflammation and Neurodegenerative Diseases 157
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines to develop functionalized ligands to target adenosine receptors: fluorescent ligands as an example 156
null 154
null 153
"Dual Anta-Inhibitors" of the A(2A) Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies 152
Discovery of simplified N2-substituted pyrazolo[3,4-d]pyrimidine derivatives as novel adenosine receptor antagonists: Efficient synthetic approaches, biological evaluations and molecular docking studies 149
Synthesis and biological evaluation of a new series of 1,2,4-Triazolo(1,5-a)-1,3,5-triazines as human A2A adenosine receptor antagonists with improved water solubility 142
null 140
The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA3 adenosine receptor antagonists: new insights into structure affinity relathionship and receptor antagonist recognition. 139
A Computational Workflow for the Identification of Novel Fragments Acting as Inhibitors of the Activity of Protein Kinase CK1δ 138
Novel fluorescent hA3 adenosine receptor antagonists. 138
Adenosine Receptor Ligands, Probes, and Functional Conjugates: A 20-Year History of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidines (PTP) 137
The A3 adenosine receptor as multifaceted therapeutic Target: pharmacology, medicinal Chemistry, and In silico approaches 135
5-Alkylamino-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines. Influence of the Substituent on the Affinity at the Adenosine Receptor Subtypes 132
The current status of pharmacotherapy for the treatment of Parkinson's disease: transition from single-target to multitarget therapy 132
Gaucher Disease: A Glance from a Medicinal Chemistry Perspective 130
Revisiting a Receptor-Based Pharmacophore Hypothesis for Human A2A Adenosine Receptor Antagonists 128
Anticonvulsivanti 127
Conjugable A3 Adenosine Receptor Antagonists: Probing the 5 Position of the Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine Scaffold. 126
Adenine derivatives as inhibitors of the casein kinase CK1delta enzyme 123
New 9-methyl-8-(4-hydroxyphenyl)adenine derivatives as A1 adenosine receptor antagonists. 123
Fluorescent ligands for adenosine receptors 121
Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands. 118
Conjugable A3 adenosine receptor antagonists for the development of functionalized ligands and their use in fluorescent probes 118
Exploring the Directionality of 5-Substitutions in a New Series of 5-Alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a Strategy to Design Novel Human A3 Adenosine Receptor Antagonists. 117
null 116
Impact of protein-ligand solvation and desolvation on transition state thermodynamic properties of adenosine A2Aligand binding kinetics 113
null 112
Novel fluorescent antagonist as a molecular probe in A3 adenosine receptor binding assays using flow cytometry. 112
Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors 112
Revisiting a Receptor-Based Pharmacophore Hypothesis for Human A2A Adenosine Receptor Antagonists. 111
Fluorescent ligands for the A3 adenosine receptor. 107
Does the combination of optimal substitutions at the C(2)-, N(5)- and N(8)-positions of the pyrazolo-triazolo-pyrimidine scaffold guaranteee selective modulation of the human A(3) adenosine receptors? 104
Pharmacophore elucidation for a new series of 2-aryl-pyrazolo-triazolo-pyrimidines as potent human A(3) adenosine receptor antagonists 103
Structural Investigations on a Novel Class of [1,2,4]Triazolo[1,5-c]pyrimidines as Adenosine Receptor Antagonists. 102
Structural Investigations on 2-Amidobenzimidazole Derivatives as New Inhibitors of Protein Kinase CK1 Delta 99
null 99
CVT 6975-like Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine Derivatives: an Attempt towards A2B Adenosine Receptor Affinity. 99
Simplification of Pyrazolo-triazolo-pyrimidine Nucleus for Searching New Adenosine Receptor Antagonists. 98
null 97
Are Two Riboses Better Than One? The Case of the Recognition and Activation of Adenosine Receptors 93
Pyrazolo-triazolo-pyrimidine Scaffold as a Molecular Passepartout for the Pan-Recognition of Human Adenosine Receptors 93
BIOMEDICAL APPLICATIONS I: DELIVERY OF DRUGS 93
null 93
7-Amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines as CK1δ inhibitors: Exploring substitutions at the 2 and 5-positions 92
null 89
Functionalized ligands targeting G protein-coupled adenosine receptors 88
Recent developments in the field of non peptidic alpha-v beta3 antagonists 85
Exploring Directionality of 5-Substitutions in a New Series of 5-Alkyamino-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a Strategy to Design Novel Human A3 Adenosine Receptors Antagonists. 85
FLUORESCENT ANTAGONISTS OF THE A3 ADENOSINE RECEPTOR 81
Riluzole-Rasagiline Hybrids: Toward the Development of Multi-Target-Directed Ligands for Amyotrophic Lateral Sclerosis 71
null 70
null 70
Promising Targets and Strategies to Control Neuroinflammation (Part I) 67
Promising Targets and Strategies to Control Neuroinflammation (Part II) 67
null 63
null 63
null 59
The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective? 57
Potent and selective A3adenosine receptor antagonists bearing aminoesters as heterobifunctional moieties 55
null 54
Acyclic purine and pyrimidine nucleotide analogs as ecto-5′-nucleotidase (CD73) inhibitors 53
Synthesis and pharmacological characyerization of a new series of 5,7-disubstituted [1,2,4]triazolo[1,5-a] [1,3,5]triazine derivatives as adenosine receptor antagonists: a preliminary inspection of ligand receptor recognition process. 48
Combining selectivity and affinity predictions using an integrated support vector machine (SVM) approach: A novel tool to discriminate between the human A2A and A3 receptor bonding sites 47
Pyrazolo derivatives as potent adenosine receptor antagonists: An overview on the structure-activity relationships 44
Receptor Driven Identifications of Novel Human A3 adenosine receptor antagonists as Potential therapeutic agents. 42
Targeting G Protein-Coupled Receptors with Magnetic Carbon Nanotubes: The Case of the A3 Adenosine Receptor 42
Exploring potency and selectivity receptor antagonist profiles using a multilabe classification approach: the human adenosine receptor as a key study 41
Totale 16.779
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.453
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.453
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021895 0 0 0 0 144 154 109 97 75 121 71 124
2021/20221.105 94 100 55 234 19 48 45 28 101 128 46 207
2022/20231.304 118 179 108 178 112 236 9 104 154 28 57 21
2023/20241.086 59 74 70 75 72 92 155 232 4 71 86 96
2024/20252.706 100 107 342 219 191 195 156 133 305 323 210 425
2025/20264.650 665 1.050 2.260 520 155 0 0 0 0 0 0 0
Totale 16.830